Industry research
CRO
Scope
US
Companies
121
Rebecca Pigula, Partner and Rowan Salter, Associate Director at CIL Strategy Consultants, provided expert insights for this report. They have extensive experience in the US CRO industry, leading several engagements for key players.
Key takeaways
What is the scope of this industry report?
The US clinical research organization (CRO) market covers businesses that offer outsourced research and development services to pharmaceutical and biotechnology companies. Companies offer services in areas of early-stage drug discovery and development, clinical trials and comprehensive support services that are crucial for efficient and compliant drug development processes. As such, we segmented the market based on players’ core service offering into: (i) discovery & preclinical, (ii) clinical, (iii) CRO support services and (iv) integrated CROs.
What does the CRO landscape look like in the US?
Competition in the overall US CRO market varies across segments. The integrated CRO segment remains highly competitive, with IQVIA leading the pack in terms of revenue, followed by Syneos Health and Medpace. Players in this segment compete on therapeutic breadth, global footprint, speed of execution and the depth of their data and technology capabilities. Larger players sustain their competitive position primarily through scale, since an extensive global infrastructure and proprietary data assets are difficult for smaller providers to replicate. The clinical CRO segment exhibits a high degree of consolidation, a structural feature traceable to the high upfront capital expenditure and scale advantages inherent in operating an established site network. Accordingly, M&A drivers include accelerated entry into high-demand specialty areas, expansion into new geographies, talent acquisition, pursuit of complementary services and related strategic considerations. By contrast, the discovery and preclinical segment remains fragmented, with large-scale platforms competing alongside numerous specialist providers. However, scale is not always a decisive advantage in discovery work, as pharma and biotech clients often split projects across multiple smaller CROs to manage IP sensitivity and avoid over-reliance on a single provider. The CRO support services market is increasingly bifurcated, with the dividing line being client size and sophistication. Smaller pharma and biotech companies continue to favor integrated propositions that bundle software and services under a single project model, with the provider owning full delivery, including the technology layer. On the other hand, large pharma clients take the opposite approach. They retain ownership of their technology infrastructure and data backbone and prefer support services providers to operate within their existing ecosystem rather than introduce proprietary platforms or parallel workflows. This drives a structural shift toward the FSP model, where the specialist capability is outsourced but the technology and data are retained in-house.
What does the CRO market landscape look like in US?
Sponsor-led interest remains high, with ~72% of identified assets being sponsor-backed (as of June 2026). Factors that attract investors include (i) the rapid integration of GenAI into core clinical development workflows, which improves trial design efficiency and clinical productivity, (ii) scaling of DCT and hybrid trial models that are designed to improve patient access, recruitment diversity and engagement, as well as (iii) regulatory support creating a growth tailwind for CROs with human-relevant testing capabilities. Deterring factors for investment include (i) the drug-pricing reform under the IRA that may reduce the economics of post-approval clinical development, (ii) budget constraints among biotech and pharmaceutical clients which can delay trial commencement, reduce study scope and deprioritize non-core development programs, as well as (iii) a persistent shortage of skilled clinical research staff that raises operating costs and constrains CRO delivery capacity.
What are the key ESG considerations in the US CRO industry?
ESG topics revolve around environmental, social and governance factors. From an environmental perspective, the industry faces challenges relating to laboratory and single-use plastic waste. Clinical and preclinical operations consume substantial energy, as laboratory facilities and ultra-low-temperature freezers draw far more power per square foot than typical office space. To address this, CROs adopt renewable energy and set science-based emissions targets, as well as redesign trial kits and lab workflows to cut plastic at the source. On the social front, the historic underrepresentation of minority and elderly populations in clinical trials weakens the generalizability of results. To improve representation, CROs deploy community-based recruitment and dedicated inclusion programs. Secondly, the treatment of animals in preclinical research remains a significant risk, with lapses in sourcing or welfare drawing regulatory and public scrutiny. To manage this risk, CROs adopt formal welfare frameworks, minimize animal use and pursue external accreditation, as well as invest in new alternative methods that replace or reduce animal use. On the governance side, lapses in how sensitive patient data is secured, shared or disclosed can lead to significant regulatory penalties. To mitigate this, CROs adopt recognized information-security standards and independent audits. Another governance concern is research misconduct at trial sites, where the fabrication or falsification of data threatens both patient safety and the integrity of regulatory submissions. To guard against this, CROs deploy AI-driven analytics and statistical monitoring to detect anomalous site data early.
Company benchmarking
Market growth
Technavio (March 2026) projects the global CRO market to grow from ~$97.6bn in 2025 to ~$149.5bn by 2030 (+8.9% CAGR 2025-2030)
The number of drugs in the global R&D pipeline grew from ~17.7k in 2020 to ~23.9k in 2025 (+6.1% CAGR 2020-2025; Pharma Linkage, June 2026; Informa PharmaIntelligence, March 2020)
Positive drivers
The rapid integration of GenAI into core clinical development workflows will improve trial design efficiency and clinical productivity. Advanced machine learning models can deliver improvements in statistical power during the initial protocol configuration phase. This near-real-time information flow and data orchestration is projected to improve clinical productivity by ~15-30%, while reducing manual administrative friction (McKinsey & Company, June 2026; McKinsey & Company, February 2025)
The scaling of DCT and hybrid trial models improves patient access, recruitment diversity and engagement while reducing fixed-site overhead. Supported by wearables, eCOA and ePRO tools, these models enhance data collection and monitoring, with predictive patient-selection algorithms that continue to deliver a ~10-20% uplift in enrollment yields (McKinsey & Company, January 2025; WCG Clinical, January 2024)
Regulatory support for New Approach Methodologies, or NAMs, creates a growth tailwind for discovery and preclinical CROs with human-relevant testing capabilities. The FDA has moved to reduce reliance on animal testing in drug development, including through greater acceptance of AI-based models, organoids, organ-on-chip systems and other non-animal approaches where scientifically justified. This benefits CROs that can combine traditional toxicology with advanced in-vitro, in-silico and microphysiological platforms (Emulate, August 2025; Pharmaceutical Outsourcing, March 2025)
Negative drivers
Drug-pricing reform under the IRA may reduce the economics of post-approval clinical development, creating a potential headwind for CROs exposed to Phase IV and lifecycle-management trials. Early evidence suggests post-approval industry-sponsored trial initiation declined following the IRA’s passage, with a sharper impact on small-molecule drugs. A sustained reduction in these studies would narrow the addressable mandate pool for clinical CROs and related support-service providers (Therapeutic Innovation & Regulatory Science, April 2025)
Budget constraints among biotech and pharmaceutical clients can limit CRO demand by delaying trial starts, reducing study scope and deprioritizing non-core development programs. This pressure may intensify as an unprecedented patent cliff exposes >$200bn in annual branded-drug revenue to generic and biosimilar competition through 2030, driving impacted pharma companies to defend margins and restrict R&D spending to their highest-priority pipeline assets (PharmExec, June 2026)
Persistent shortages of skilled clinical research staff raise operating costs and constrain CRO delivery capacity. Life sciences was named the most talent-scarce industry globally in 2026, with ~77% of employers reporting difficulty finding qualified people, compounded by an annual site-based clinical research staff turnover rate of ~35-61% and an average tenure of just ~1.5-2 years (Clinovo, April 2026; SCRS, April 2025)
Fill out the form to request your copy of the CRO industry report
With the full report, you’ll gain access to:
Detailed assessments of the market outlook
Insights from c-suite industry executives
A clear overview of all active investors in the industry
An in-depth look into 121 private companies, incl. financials, ownership details and more.
A view on all 557 deals in the industry
ESG assessments with highlighted ESG outperformers
Discover hundreds of niche industry reports on Gain
Deep dive into additional industries to understand their market outlook, positive and negative drivers, and more!
